180 related articles for article (PubMed ID: 16319023)
1. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements.
de Carvalho M; Costa J; Swash M
Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Dec; 6(4):202-12. PubMed ID: 16319023
[TBL] [Abstract][Full Text] [Related]
2. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials.
de Carvalho M; Chio A; Dengler R; Hecht M; Weber M; Swash M
Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):17-28. PubMed ID: 16036422
[TBL] [Abstract][Full Text] [Related]
3. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
de Carvalho M; Swash M
Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
[TBL] [Abstract][Full Text] [Related]
4. The use of statistical MUNE in a multicenter clinical trial.
Shefner JM; Cudkowicz ME; Zhang H; Schoenfeld D; Jillapalli D;
Muscle Nerve; 2004 Oct; 30(4):463-9. PubMed ID: 15316983
[TBL] [Abstract][Full Text] [Related]
5. The Neurophysiological Index in ALS.
Swash M; de Carvalho M
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():108-10. PubMed ID: 15512888
[TBL] [Abstract][Full Text] [Related]
6. Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis.
Sanjak M; Salachas F; Frija-Orvoen E; Theys P; Hutchinson D; Verheijde J; Pianta T; Stewart H; Brooks BR; Meininger V; Douillet P;
Amyotroph Lateral Scler; 2010 Aug; 11(4):383-8. PubMed ID: 20192884
[TBL] [Abstract][Full Text] [Related]
7. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
8. Improving efficiency of ALS clinical trials using lead-in designs.
Moore DH; Miller RG
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875
[TBL] [Abstract][Full Text] [Related]
9. Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis.
Liu XX; Zhang J; Zheng JY; Zhang S; Xu YS; Kang DX; Fan DS
Muscle Nerve; 2009 Mar; 39(3):304-9. PubMed ID: 19208412
[TBL] [Abstract][Full Text] [Related]
10. The natural history of ALS is changing: improved survival.
Qureshi M; Schoenfeld DA; Paliwal Y; Shui A; Cudkowicz ME
Amyotroph Lateral Scler; 2009; 10(5-6):324-31. PubMed ID: 19922119
[TBL] [Abstract][Full Text] [Related]
11. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
[TBL] [Abstract][Full Text] [Related]
12. The value of database controls in pilot or futility studies in ALS.
Czaplinski A; Haverkamp LJ; Yen AA; Simpson EP; Lai EC; Appel SH
Neurology; 2006 Nov; 67(10):1827-32. PubMed ID: 17130417
[TBL] [Abstract][Full Text] [Related]
13. Selecting promising ALS therapies in clinical trials.
Cheung YK; Gordon PH; Levin B
Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
[TBL] [Abstract][Full Text] [Related]
14. Scrutinizing enrollment in ALS clinical trials: room for improvement?
Bedlack RS; Pastula DM; Welsh E; Pulley D; Cudkowicz ME
Amyotroph Lateral Scler; 2008 Oct; 9(5):257-65. PubMed ID: 18608092
[TBL] [Abstract][Full Text] [Related]
15. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.
Leigh PN; Swash M; Iwasaki Y; Ludolph A; Meininger V; Miller RG; Mitsumoto H; Shaw P; Tashiro K; Van Den Berg L
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Jun; 5(2):84-98. PubMed ID: 15204010
[TBL] [Abstract][Full Text] [Related]
16. Outcome measures for early phase clinical trials.
Gordon PH; Cheng B; Montes J; Doorish C; Albert SM; Mitsumoto H
Amyotroph Lateral Scler; 2007 Oct; 8(5):270-3. PubMed ID: 17852017
[TBL] [Abstract][Full Text] [Related]
17. Design of phase II ALS clinical trials.
Schoenfeld DA; Cudkowicz M
Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
[TBL] [Abstract][Full Text] [Related]
18. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study.
Huang H; Chen L; Xi H; Wang H; Zhang J; Zhang F; Liu Y
Clin Transplant; 2008; 22(6):710-8. PubMed ID: 18673377
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
Levin BJ; Thompson G; Mitsumoto LH; Kaufmann P
Neurology; 2006 Jun; 66(11):1786-7; author reply 1786-7. PubMed ID: 16769973
[No Abstract] [Full Text] [Related]
20. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
